COVID-19 pandemic crisis-a complete outline of SARS-CoV-2

被引:1
作者
Shaikh, Sana Saffiruddin [1 ]
Jose, Anooja P. [2 ]
Nerkar, Disha Anil [2 ]
Vijaykumar KV, Midhuna [2 ]
Shaikh, Saquib Khaleel [1 ]
机构
[1] YB Chavan Coll Pharm, Dr Rafiq Zakaria Campus, Aurangabad 431001, Maharashtra, India
[2] Govt Coll Pharm, Aurangabad 431001, Maharashtra, India
关键词
COVID-19; SARS-CoV-2; Lifecycle; Pathogenesis; Prevention; Clinical trials; CORONAVIRUS DISEASE 2019; CLINICAL CHARACTERISTICS;
D O I
10.1186/s43094-020-00133-y
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Coronavirus (SARS-CoV-2), the cause of COVID-19, a fatal disease emerged from Wuhan, a large city in the Chinese province of Hubei in December 2019. Main body of abstract: The World Health Organization declared COVID-19 as a pandemic due to its spread to other countries inside and outside Asia. Initial confirmation of the pandemic shows patient exposure to the Huanan seafood market. Bats might be a significant host for the spread of coronaviruses via an unknown intermediate host. The human-to-human transfer has become a significant concern due to one of the significant reasons that is asymptomatic carriers or silent spreaders. No data is obtained regarding prophylactic treatment for COVID-19, although many clinical trials are underway. Conclusion: The most effective weapon is prevention and precaution to avoid the spread of the pandemic. In this current review, we outline pathogenesis, diagnosis, treatment, ongoing clinical trials, prevention, and precautions. We have also highlighted the impact of pandemic worldwide and challenges that can help to overcome the fatal disease in the future.
引用
收藏
页数:20
相关论文
共 117 条
[1]   Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review [J].
Adhikari, Sasmita Poudel ;
Meng, Sha ;
Wu, Yu-Ju ;
Mao, Yu-Ping ;
Ye, Rui-Xue ;
Wang, Qing-Zhi ;
Sun, Chang ;
Sylvia, Sean ;
Rozelle, Scott ;
Raat, Hein ;
Zhou, Huan .
INFECTIOUS DISEASES OF POVERTY, 2020, 9 (01)
[2]   Tocilizumab for the treatment of severe coronavirus disease 2019 [J].
Alattar, Rand ;
Ibrahim, Tawheeda B. H. ;
Shaar, Shahd H. ;
Abdalla, Shiema ;
Shukri, Kinda ;
Daghfal, Joanne N. ;
Khatib, Mohamed Y. ;
Aboukamar, Mohamed ;
Abukhattab, Mohamed ;
Alsoub, Hussam A. ;
Almaslamani, Muna A. ;
Omrani, Ali S. .
JOURNAL OF MEDICAL VIROLOGY, 2020, 92 (10) :2042-2049
[3]  
Allison LT, 2012, CURR OPIN VIROL, V2, P264, DOI [10.1016/j.coviro.2012.04.004, DOI 10.1016/J.COVIRO.2012.04.004]
[4]  
Ana S., 2020, MED NEWS TODAY
[5]  
Anand K B., 2020, Medical Journal Armed Forces India, V76, P136, DOI DOI 10.1016/J.MJAFI.2020.04.008
[6]   The proximal origin of SARS-CoV-2 [J].
Andersen, Kristian G. ;
Rambaut, Andrew ;
Lipkin, W. Ian ;
Holmes, Edward C. ;
Garry, Robert F. .
NATURE MEDICINE, 2020, 26 (04) :450-452
[7]   Challenges of coronavirus disease 2019 [J].
不详 .
LANCET INFECTIOUS DISEASES, 2020, 20 (03) :261-261
[8]  
[Anonymous], Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected
[9]  
[Anonymous], COR DIS 2019 TEST CU
[10]  
[Anonymous], COR DIS 2019 TEST CO